Mark Fishman is an American cardiologist, a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the Massachusetts General Hospital for patients with complex medical disorders.
[3] Fishman was appointed president of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort.
[4] He is the author of over 100 publications[5] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease.
[6][7][8] He was previously a professor of medicine at Harvard Medical School, chief of cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital.
[9] After being the head of Novartis’ research operation for 13 years, he decided to retire in 2016[10] and became professor at Harvard and Chief at MGH[1]